Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (443)	6/7/2004 4:18:50 PM
From: quidditch	Read Replies (1) \| Respond to of 933

Peter: well, that BMS epothilone poster didn't help KOSN by invidious reference (:- Unless Sunday's posters were expected to contain some anecdotal efficacy data, or unless today's morning presentation at the conference disappointed, I'm a bit at a loss to understand the market reaction today. Was this a "sell the lack of news"? Or were analysts looking for some indication of efficacy from preliminary results of these early trials of 17AAG? Or, is there a leak as to tomorrow's discussion of P1 results of Epoth 862? quid